Evidence map›Paper›PMID 38802638›Full record

ArticleEuropean journal of clinical pharmacology2024

Trends in statin use for the primary prevention of atherosclerotic cardiovascular disease among US adults by demographic characteristics, 1999-2020.

Junwen Wang, Yuyang Ye, Xuefeng Chen, Xinru Hu, Yong Peng

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Junwen WangDepartment of Cardiology, West China Hospital, Sichuan University, 37 Guoxue Street, Chengdu, 610041, China.ORCID http://orcid.org/0000-0003-2426-8944
Yuyang YeDepartment of Cardiology, West China Hospital, Sichuan University, 37 Guoxue Street, Chengdu, 610041, China.
Xuefeng ChenDepartment of Cardiology, West China Hospital, Sichuan University, 37 Guoxue Street, Chengdu, 610041, China.
Xinru HuDepartment of Cardiology, West China Hospital, Sichuan University, 37 Guoxue Street, Chengdu, 610041, China.
Yong PengDepartment of Cardiology, West China Hospital, Sichuan University, 37 Guoxue Street, Chengdu, 610041, China. pengyong@scu.edu.cn.ORCID http://orcid.org/0000-0001-9562-4622

Funding

1·3·5 project for disciplines of excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University 2021HXFH061Sichuan Provincial Cadre Health Research Project, China Sichuan Ganyan ZH2024-101
6 · The paper itself

Abstract

purposeAtherosclerotic cardiovascular disease (ASCVD) is a leading cause of mortality worldwide. Statins, which are effective in preventing ASCVD, are underused, particularly for primary prevention. This study examined trends in statin use for primary ASCVD prevention from 1999 to 2020, focusing on demographic variations.

methodsUtilizing data from the National Health and Nutrition Examination Survey, the present study includes individuals aged 18 years and older who had a greater than 10% risk of ASCVD over 10 years, and excluded patients with existing ASCVD. Subgroup analyses by demographic categories were performed. We calculated the changes in statin usage and used linear and quadratic tests to assess the linear and nonlinear trends in those changes.

resultsA total of 10,037 participants were included. Statin usage increased from 16.16% in 1999 to 36.24% in 2010, and 41.74% in 2020 (quadratic P-value < 0.001). In the 18-44 years age group, statin usage increased from 2.52% in 1999 to 8.14% in 2020 (linear P-value = 0.322), showing no significant linear trend. In the "never-married" group, statin usage increased from 19.16% in 1999 to 30.05% in 2020 (linear P-value = 0.256).

conclusionStatin usage has shown a positive trend among populations requiring primary prevention for ASCVD. Currently, health policies are proving effective. However, the overall statin usage rate remains less than 50%. Additionally, young and never-married individuals should also receive special attention regarding statin usage as primary treatment for ASCVD.

Indexed as

AtherosclerosisHydroxymethylglutaryl-CoA Reductase InhibitorsNutrition SurveysPrimary PreventionAdolescentAdultAgedCardiovascular DiseasesFemaleHumansMaleMiddle AgedUnited StatesYoung AdultHydroxymethylglutaryl-CoA Reductase InhibitorsAtherosclerosis cardiovascular diseaseDemographic characteristicsHealth policiesPrimary preventionStatin utilization

Identifiers

PMID38802638

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.